Key Insights
The global cancer biopsy market, valued at $29.93 billion in 2025, is projected to experience robust growth, driven by a compound annual growth rate (CAGR) of 11.46% from 2025 to 2033. This expansion is fueled by several key factors. The rising incidence of various cancers, particularly breast, colorectal, cervical, and lung cancers, globally is a primary driver. Technological advancements in biopsy techniques, such as liquid biopsy and minimally invasive procedures, are improving diagnostic accuracy and patient outcomes, further stimulating market growth. The increasing adoption of advanced imaging technologies for precise biopsy targeting and the growing preference for personalized medicine, which relies heavily on biopsy results for tailored treatment strategies, are also significant contributors. Furthermore, the expansion of healthcare infrastructure, particularly in developing economies, and the rising awareness among patients about early cancer detection are positively impacting market expansion. The market is segmented by application (cancer type), end-user (hospitals, diagnostic labs), product (instruments, kits, services), and biopsy type (tissue, surgical, liquid). Each segment presents unique growth opportunities, with liquid biopsy, for example, showing significant promise due to its minimally invasive nature and potential for early cancer detection.
Cancer Biopsy Industry Market Size (In Billion)
Competition in the cancer biopsy market is intense, with major players including Becton Dickinson, Myriad Genetics, Hologic, and Illumina, among others. These companies are engaged in continuous innovation, focusing on developing advanced biopsy technologies and expanding their geographic reach to capitalize on the market's growth potential. However, challenges remain, including the high cost of advanced biopsy procedures and the need for skilled personnel to perform these procedures, potentially limiting market penetration in certain regions. Regulatory hurdles and reimbursement policies also influence market dynamics. Despite these constraints, the long-term outlook for the cancer biopsy market remains positive, driven by the persistent rise in cancer incidence and the ongoing development of innovative biopsy technologies that promise earlier, more precise diagnoses and improved treatment outcomes.
Cancer Biopsy Industry Company Market Share
Cancer Biopsy Industry Market Report: 2019-2033
This comprehensive report provides a detailed analysis of the Cancer Biopsy Industry, encompassing market dynamics, growth trends, regional segmentation, product landscape, key players, and future outlook. The study period covers 2019-2033, with 2025 as the base and estimated year. The report segments the market by application (Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Other Applications), end-user (Hospitals, Diagnostic Laboratories, Other End Users), product (Instruments, Kits and Consumables, Services), and type (Tissue Biopsy, Surgical Biopsy, Liquid Biopsy, Other Types). The market is valued in million USD.
Cancer Biopsy Industry Market Dynamics & Structure
The cancer biopsy market is characterized by a moderately concentrated landscape with a few dominant players and numerous smaller niche companies. Technological innovation, particularly in liquid biopsy, is a key driver, alongside stringent regulatory frameworks governing diagnostic procedures. The market witnesses consistent M&A activity, reflecting the quest for expanded market share and technological capabilities. Competitive product substitutes, such as advanced imaging techniques, pose a challenge. End-user demographics, largely influenced by aging populations and rising cancer incidence rates, fuel market growth.
- Market Concentration: xx% market share held by the top 5 players in 2024.
- Technological Innovation: Rapid advancements in liquid biopsy, minimally invasive techniques, and AI-driven diagnostics are reshaping the market.
- Regulatory Landscape: Stringent regulatory approvals (e.g., FDA clearances) and reimbursement policies influence market access and growth.
- M&A Activity: An average of xx M&A deals were recorded annually between 2019 and 2024.
- Competitive Substitutes: Advanced imaging techniques like PET scans offer alternative diagnostic options.
- Innovation Barriers: High R&D costs, lengthy regulatory pathways, and the need for extensive clinical validation hinder innovation.
Cancer Biopsy Industry Growth Trends & Insights
The global cancer biopsy market witnessed robust growth from 2019 to 2024, fueled by a confluence of factors: the escalating global cancer burden, groundbreaking technological advancements, and a steady rise in healthcare expenditure. Market projections indicate a continued expansion, with a projected Compound Annual Growth Rate (CAGR) of xx% from 2025 to 2033, culminating in a market value of xx million USD by 2033. This growth is significantly propelled by the increasing adoption of liquid biopsies, prized for their minimally invasive nature and potential for early cancer detection. Furthermore, evolving consumer behavior, characterized by heightened awareness and a growing demand for personalized medicine, is acting as a powerful catalyst for market expansion. The integration of artificial intelligence (AI) and big data analytics is poised to revolutionize the field, promising significant enhancements in diagnostic accuracy and efficiency. While the market penetration of advanced biopsy techniques remains relatively low at present, it shows immense potential for substantial future growth.
Dominant Regions, Countries, or Segments in Cancer Biopsy Industry
North America currently holds a dominant position in the cancer biopsy market, driven by factors such as high healthcare expenditure, rapid technological advancements, and well-established regulatory frameworks. However, the Asia-Pacific region is emerging as a significant growth market, fueled by rising cancer incidence rates, substantial investments in healthcare infrastructure, and a burgeoning middle class with improved access to healthcare services. A detailed segmental analysis reveals the following:
- By Application: Breast cancer and lung cancer currently represent the largest application segments, reflecting their high prevalence rates.
- By End-User: Hospitals and diagnostic laboratories constitute the primary end-users of cancer biopsy services and products.
- By Product: Kits and consumables are the leading product segment, driven by the high demand for various diagnostic tests.
- By Type: While tissue biopsy remains the largest segment currently, liquid biopsy is experiencing exceptionally rapid growth, transforming the diagnostic landscape.
Key Market Drivers:
- High and rising global cancer prevalence rates
- Continuously increasing healthcare expenditure worldwide
- Growing adoption of advanced and innovative diagnostic technologies
- Supportive regulatory environments, particularly in North America, fostering innovation
- Escalating public awareness regarding early cancer detection and its importance
Cancer Biopsy Industry Product Landscape
The cancer biopsy market offers a diverse range of products, including instruments (e.g., biopsy needles, automated biopsy systems), kits and consumables (e.g., reagents, stains, slides), and services (e.g., biopsy analysis, interpretation). Recent innovations have focused on minimally invasive techniques, such as liquid biopsy, enabling early cancer detection and reducing patient discomfort. Unique selling propositions often center around improved accuracy, faster turnaround times, and enhanced ease of use. Technological advancements like AI-powered image analysis are improving diagnostic accuracy and efficiency.
Key Drivers, Barriers & Challenges in Cancer Biopsy Industry
Key Drivers:
- Rising prevalence of cancer globally.
- Technological advancements in minimally invasive biopsy techniques.
- Increasing demand for early cancer detection and personalized medicine.
- Favorable regulatory environments in developed countries.
Challenges and Restraints:
- High cost of advanced biopsy procedures and technologies.
- Stringent regulatory approval processes.
- Skilled personnel shortages for specialized procedures.
- Potential reimbursement challenges in certain healthcare systems. This leads to a xx% reduction in market growth annually.
Emerging Opportunities in Cancer Biopsy Industry
- Liquid Biopsy Expansion: Continued research and development, coupled with broader clinical adoption of liquid biopsy techniques, particularly for early cancer detection and ongoing disease monitoring, presents a significant opportunity.
- AI-Powered Diagnostics: The integration of artificial intelligence and machine learning algorithms holds immense potential for improving diagnostic accuracy, streamlining workflows, and accelerating turnaround times.
- Personalized Medicine: The development of customized biopsy strategies, tailored to individual patient characteristics and specific cancer types, represents a key area of future growth.
- Point-of-Care Diagnostics: The development of rapid and portable biopsy devices for use in remote areas or point-of-care settings will enhance accessibility and improve patient outcomes.
- Multi-omics Analysis: Integration of genomics, proteomics, and metabolomics data with biopsy results to deliver more comprehensive diagnostic insights.
Growth Accelerators in the Cancer Biopsy Industry
The cancer biopsy market is poised for sustained growth due to technological breakthroughs in liquid biopsy and minimally invasive techniques. Strategic partnerships between diagnostic companies and pharmaceutical firms are driving innovation and market expansion. The increasing focus on early cancer detection and personalized medicine provides significant growth potential. Further expansion into emerging markets will fuel market expansion.
Key Players Shaping the Cancer Biopsy Industry Market
Notable Milestones in Cancer Biopsy Industry Sector
- August 2022: Guardant Health receives US FDA approval for its Guardant360 CDx liquid biopsy test for HER2-mutant NSCLC.
- May 2022: Delfi Diagnostics presents trial-in-progress update on DELFI-L101 for lung cancer detection using liquid biopsy.
In-Depth Cancer Biopsy Industry Market Outlook
The cancer biopsy market is poised for sustained and robust growth throughout the next decade, propelled by continuous technological innovations, the persistently high global cancer prevalence, and expanding access to advanced healthcare services worldwide. The competitive landscape will be significantly shaped by strategic mergers and acquisitions, collaborative partnerships, and the ongoing development of cutting-edge diagnostic tools. The increasing emphasis on minimally invasive procedures and early cancer detection presents substantial opportunities for existing and emerging market players. The market's projected value of xx million USD by 2033 underscores the significant growth potential for investors and industry stakeholders alike.
Cancer Biopsy Industry Segmentation
-
1. Product
- 1.1. Instruments
- 1.2. Kits and Consumables
- 1.3. Services
-
2. Type
- 2.1. Tissue Biopsy
- 2.2. Surgical Biopsy
- 2.3. Liquid Biopsy
- 2.4. Other Types
-
3. Application
- 3.1. Breast Cancer
- 3.2. Colorectal Cancer
- 3.3. Cervical Cancers
- 3.4. Lung Cancers
- 3.5. Other Applications
-
4. End User
- 4.1. Hospitals
- 4.2. Diagnostic Laboratories
- 4.3. Other End Users
Cancer Biopsy Industry Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. Europe
- 2.1. Germany
- 2.2. United Kingdom
- 2.3. France
- 2.4. Italy
- 2.5. Spain
- 2.6. Rest of Europe
-
3. Asia Pacific
- 3.1. China
- 3.2. Japan
- 3.3. India
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia Pacific
-
4. Middle East and Africa
- 4.1. GCC
- 4.2. South Africa
- 4.3. Rest of Middle East and Africa
-
5. South America
- 5.1. Brazil
- 5.2. Argentina
- 5.3. Rest of South America
Cancer Biopsy Industry Regional Market Share
Geographic Coverage of Cancer Biopsy Industry
Cancer Biopsy Industry REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 11.46% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Objective
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Market Snapshot
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restrains
- 3.3. Market Trends
- 3.4. Market Opportunities
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.2. PESTEL analysis
- 4.3. BCG Analysis
- 4.3.1. Stars (High Growth, High Market Share)
- 4.3.2. Cash Cows (Low Growth, High Market Share)
- 4.3.3. Question Mark (High Growth, Low Market Share)
- 4.3.4. Dogs (Low Growth, Low Market Share)
- 4.4. Ansoff Matrix Analysis
- 4.5. Supply Chain Analysis
- 4.6. Regulatory Landscape
- 4.7. Current Market Potential and Opportunity Assessment (TAM–SAM–SOM Framework)
- 4.8. IMR Analyst Note
- 4.1. Porters Five Forces
- 5. Market Analysis, Insights and Forecast 2021-2033
- 5.1. Market Analysis, Insights and Forecast - by Product
- 5.1.1. Instruments
- 5.1.2. Kits and Consumables
- 5.1.3. Services
- 5.2. Market Analysis, Insights and Forecast - by Type
- 5.2.1. Tissue Biopsy
- 5.2.2. Surgical Biopsy
- 5.2.3. Liquid Biopsy
- 5.2.4. Other Types
- 5.3. Market Analysis, Insights and Forecast - by Application
- 5.3.1. Breast Cancer
- 5.3.2. Colorectal Cancer
- 5.3.3. Cervical Cancers
- 5.3.4. Lung Cancers
- 5.3.5. Other Applications
- 5.4. Market Analysis, Insights and Forecast - by End User
- 5.4.1. Hospitals
- 5.4.2. Diagnostic Laboratories
- 5.4.3. Other End Users
- 5.5. Market Analysis, Insights and Forecast - by Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Middle East and Africa
- 5.5.5. South America
- 5.1. Market Analysis, Insights and Forecast - by Product
- 6. Global Cancer Biopsy Industry Analysis, Insights and Forecast, 2021-2033
- 6.1. Market Analysis, Insights and Forecast - by Product
- 6.1.1. Instruments
- 6.1.2. Kits and Consumables
- 6.1.3. Services
- 6.2. Market Analysis, Insights and Forecast - by Type
- 6.2.1. Tissue Biopsy
- 6.2.2. Surgical Biopsy
- 6.2.3. Liquid Biopsy
- 6.2.4. Other Types
- 6.3. Market Analysis, Insights and Forecast - by Application
- 6.3.1. Breast Cancer
- 6.3.2. Colorectal Cancer
- 6.3.3. Cervical Cancers
- 6.3.4. Lung Cancers
- 6.3.5. Other Applications
- 6.4. Market Analysis, Insights and Forecast - by End User
- 6.4.1. Hospitals
- 6.4.2. Diagnostic Laboratories
- 6.4.3. Other End Users
- 6.1. Market Analysis, Insights and Forecast - by Product
- 7. North America Cancer Biopsy Industry Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Product
- 7.1.1. Instruments
- 7.1.2. Kits and Consumables
- 7.1.3. Services
- 7.2. Market Analysis, Insights and Forecast - by Type
- 7.2.1. Tissue Biopsy
- 7.2.2. Surgical Biopsy
- 7.2.3. Liquid Biopsy
- 7.2.4. Other Types
- 7.3. Market Analysis, Insights and Forecast - by Application
- 7.3.1. Breast Cancer
- 7.3.2. Colorectal Cancer
- 7.3.3. Cervical Cancers
- 7.3.4. Lung Cancers
- 7.3.5. Other Applications
- 7.4. Market Analysis, Insights and Forecast - by End User
- 7.4.1. Hospitals
- 7.4.2. Diagnostic Laboratories
- 7.4.3. Other End Users
- 7.1. Market Analysis, Insights and Forecast - by Product
- 8. Europe Cancer Biopsy Industry Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Product
- 8.1.1. Instruments
- 8.1.2. Kits and Consumables
- 8.1.3. Services
- 8.2. Market Analysis, Insights and Forecast - by Type
- 8.2.1. Tissue Biopsy
- 8.2.2. Surgical Biopsy
- 8.2.3. Liquid Biopsy
- 8.2.4. Other Types
- 8.3. Market Analysis, Insights and Forecast - by Application
- 8.3.1. Breast Cancer
- 8.3.2. Colorectal Cancer
- 8.3.3. Cervical Cancers
- 8.3.4. Lung Cancers
- 8.3.5. Other Applications
- 8.4. Market Analysis, Insights and Forecast - by End User
- 8.4.1. Hospitals
- 8.4.2. Diagnostic Laboratories
- 8.4.3. Other End Users
- 8.1. Market Analysis, Insights and Forecast - by Product
- 9. Asia Pacific Cancer Biopsy Industry Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Product
- 9.1.1. Instruments
- 9.1.2. Kits and Consumables
- 9.1.3. Services
- 9.2. Market Analysis, Insights and Forecast - by Type
- 9.2.1. Tissue Biopsy
- 9.2.2. Surgical Biopsy
- 9.2.3. Liquid Biopsy
- 9.2.4. Other Types
- 9.3. Market Analysis, Insights and Forecast - by Application
- 9.3.1. Breast Cancer
- 9.3.2. Colorectal Cancer
- 9.3.3. Cervical Cancers
- 9.3.4. Lung Cancers
- 9.3.5. Other Applications
- 9.4. Market Analysis, Insights and Forecast - by End User
- 9.4.1. Hospitals
- 9.4.2. Diagnostic Laboratories
- 9.4.3. Other End Users
- 9.1. Market Analysis, Insights and Forecast - by Product
- 10. Middle East and Africa Cancer Biopsy Industry Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Product
- 10.1.1. Instruments
- 10.1.2. Kits and Consumables
- 10.1.3. Services
- 10.2. Market Analysis, Insights and Forecast - by Type
- 10.2.1. Tissue Biopsy
- 10.2.2. Surgical Biopsy
- 10.2.3. Liquid Biopsy
- 10.2.4. Other Types
- 10.3. Market Analysis, Insights and Forecast - by Application
- 10.3.1. Breast Cancer
- 10.3.2. Colorectal Cancer
- 10.3.3. Cervical Cancers
- 10.3.4. Lung Cancers
- 10.3.5. Other Applications
- 10.4. Market Analysis, Insights and Forecast - by End User
- 10.4.1. Hospitals
- 10.4.2. Diagnostic Laboratories
- 10.4.3. Other End Users
- 10.1. Market Analysis, Insights and Forecast - by Product
- 11. South America Cancer Biopsy Industry Analysis, Insights and Forecast, 2020-2032
- 11.1. Market Analysis, Insights and Forecast - by Product
- 11.1.1. Instruments
- 11.1.2. Kits and Consumables
- 11.1.3. Services
- 11.2. Market Analysis, Insights and Forecast - by Type
- 11.2.1. Tissue Biopsy
- 11.2.2. Surgical Biopsy
- 11.2.3. Liquid Biopsy
- 11.2.4. Other Types
- 11.3. Market Analysis, Insights and Forecast - by Application
- 11.3.1. Breast Cancer
- 11.3.2. Colorectal Cancer
- 11.3.3. Cervical Cancers
- 11.3.4. Lung Cancers
- 11.3.5. Other Applications
- 11.4. Market Analysis, Insights and Forecast - by End User
- 11.4.1. Hospitals
- 11.4.2. Diagnostic Laboratories
- 11.4.3. Other End Users
- 11.1. Market Analysis, Insights and Forecast - by Product
- 12. Competitive Analysis
- 12.1. Company Profiles
- 12.1.1 Becton Dickinson and Company
- 12.1.1.1. Company Overview
- 12.1.1.2. Products
- 12.1.1.3. Company Financials
- 12.1.1.4. SWOT Analysis
- 12.1.2 Myriad Genetics Inc
- 12.1.2.1. Company Overview
- 12.1.2.2. Products
- 12.1.2.3. Company Financials
- 12.1.2.4. SWOT Analysis
- 12.1.3 BIOCEPT INC
- 12.1.3.1. Company Overview
- 12.1.3.2. Products
- 12.1.3.3. Company Financials
- 12.1.3.4. SWOT Analysis
- 12.1.4 Hologic Inc
- 12.1.4.1. Company Overview
- 12.1.4.2. Products
- 12.1.4.3. Company Financials
- 12.1.4.4. SWOT Analysis
- 12.1.5 ANGLE PLC
- 12.1.5.1. Company Overview
- 12.1.5.2. Products
- 12.1.5.3. Company Financials
- 12.1.5.4. SWOT Analysis
- 12.1.6 Danaher Corporation
- 12.1.6.1. Company Overview
- 12.1.6.2. Products
- 12.1.6.3. Company Financials
- 12.1.6.4. SWOT Analysis
- 12.1.7 Agilent Technologies Inc
- 12.1.7.1. Company Overview
- 12.1.7.2. Products
- 12.1.7.3. Company Financials
- 12.1.7.4. SWOT Analysis
- 12.1.8 Lucence Diagnostics Pte Ltd
- 12.1.8.1. Company Overview
- 12.1.8.2. Products
- 12.1.8.3. Company Financials
- 12.1.8.4. SWOT Analysis
- 12.1.9 Sysmex Corporation
- 12.1.9.1. Company Overview
- 12.1.9.2. Products
- 12.1.9.3. Company Financials
- 12.1.9.4. SWOT Analysis
- 12.1.10 MDx Health
- 12.1.10.1. Company Overview
- 12.1.10.2. Products
- 12.1.10.3. Company Financials
- 12.1.10.4. SWOT Analysis
- 12.1.11 Illumina Inc
- 12.1.11.1. Company Overview
- 12.1.11.2. Products
- 12.1.11.3. Company Financials
- 12.1.11.4. SWOT Analysis
- 12.1.12 Thermo Fisher Scientific
- 12.1.12.1. Company Overview
- 12.1.12.2. Products
- 12.1.12.3. Company Financials
- 12.1.12.4. SWOT Analysis
- 12.1.13 QIAGEN
- 12.1.13.1. Company Overview
- 12.1.13.2. Products
- 12.1.13.3. Company Financials
- 12.1.13.4. SWOT Analysis
- 12.1.1 Becton Dickinson and Company
- 12.2. Market Entropy
- 12.2.1 Company's Key Areas Served
- 12.2.2 Recent Developments
- 12.3. Company Market Share Analysis 2025
- 12.3.1 Top 5 Companies Market Share Analysis
- 12.3.2 Top 3 Companies Market Share Analysis
- 12.4. List of Potential Customers
- 13. Research Methodology
List of Figures
- Figure 1: Global Cancer Biopsy Industry Revenue Breakdown (Million, %) by Region 2025 & 2033
- Figure 2: Global Cancer Biopsy Industry Volume Breakdown (K Unit, %) by Region 2025 & 2033
- Figure 3: North America Cancer Biopsy Industry Revenue (Million), by Product 2025 & 2033
- Figure 4: North America Cancer Biopsy Industry Volume (K Unit), by Product 2025 & 2033
- Figure 5: North America Cancer Biopsy Industry Revenue Share (%), by Product 2025 & 2033
- Figure 6: North America Cancer Biopsy Industry Volume Share (%), by Product 2025 & 2033
- Figure 7: North America Cancer Biopsy Industry Revenue (Million), by Type 2025 & 2033
- Figure 8: North America Cancer Biopsy Industry Volume (K Unit), by Type 2025 & 2033
- Figure 9: North America Cancer Biopsy Industry Revenue Share (%), by Type 2025 & 2033
- Figure 10: North America Cancer Biopsy Industry Volume Share (%), by Type 2025 & 2033
- Figure 11: North America Cancer Biopsy Industry Revenue (Million), by Application 2025 & 2033
- Figure 12: North America Cancer Biopsy Industry Volume (K Unit), by Application 2025 & 2033
- Figure 13: North America Cancer Biopsy Industry Revenue Share (%), by Application 2025 & 2033
- Figure 14: North America Cancer Biopsy Industry Volume Share (%), by Application 2025 & 2033
- Figure 15: North America Cancer Biopsy Industry Revenue (Million), by End User 2025 & 2033
- Figure 16: North America Cancer Biopsy Industry Volume (K Unit), by End User 2025 & 2033
- Figure 17: North America Cancer Biopsy Industry Revenue Share (%), by End User 2025 & 2033
- Figure 18: North America Cancer Biopsy Industry Volume Share (%), by End User 2025 & 2033
- Figure 19: North America Cancer Biopsy Industry Revenue (Million), by Country 2025 & 2033
- Figure 20: North America Cancer Biopsy Industry Volume (K Unit), by Country 2025 & 2033
- Figure 21: North America Cancer Biopsy Industry Revenue Share (%), by Country 2025 & 2033
- Figure 22: North America Cancer Biopsy Industry Volume Share (%), by Country 2025 & 2033
- Figure 23: Europe Cancer Biopsy Industry Revenue (Million), by Product 2025 & 2033
- Figure 24: Europe Cancer Biopsy Industry Volume (K Unit), by Product 2025 & 2033
- Figure 25: Europe Cancer Biopsy Industry Revenue Share (%), by Product 2025 & 2033
- Figure 26: Europe Cancer Biopsy Industry Volume Share (%), by Product 2025 & 2033
- Figure 27: Europe Cancer Biopsy Industry Revenue (Million), by Type 2025 & 2033
- Figure 28: Europe Cancer Biopsy Industry Volume (K Unit), by Type 2025 & 2033
- Figure 29: Europe Cancer Biopsy Industry Revenue Share (%), by Type 2025 & 2033
- Figure 30: Europe Cancer Biopsy Industry Volume Share (%), by Type 2025 & 2033
- Figure 31: Europe Cancer Biopsy Industry Revenue (Million), by Application 2025 & 2033
- Figure 32: Europe Cancer Biopsy Industry Volume (K Unit), by Application 2025 & 2033
- Figure 33: Europe Cancer Biopsy Industry Revenue Share (%), by Application 2025 & 2033
- Figure 34: Europe Cancer Biopsy Industry Volume Share (%), by Application 2025 & 2033
- Figure 35: Europe Cancer Biopsy Industry Revenue (Million), by End User 2025 & 2033
- Figure 36: Europe Cancer Biopsy Industry Volume (K Unit), by End User 2025 & 2033
- Figure 37: Europe Cancer Biopsy Industry Revenue Share (%), by End User 2025 & 2033
- Figure 38: Europe Cancer Biopsy Industry Volume Share (%), by End User 2025 & 2033
- Figure 39: Europe Cancer Biopsy Industry Revenue (Million), by Country 2025 & 2033
- Figure 40: Europe Cancer Biopsy Industry Volume (K Unit), by Country 2025 & 2033
- Figure 41: Europe Cancer Biopsy Industry Revenue Share (%), by Country 2025 & 2033
- Figure 42: Europe Cancer Biopsy Industry Volume Share (%), by Country 2025 & 2033
- Figure 43: Asia Pacific Cancer Biopsy Industry Revenue (Million), by Product 2025 & 2033
- Figure 44: Asia Pacific Cancer Biopsy Industry Volume (K Unit), by Product 2025 & 2033
- Figure 45: Asia Pacific Cancer Biopsy Industry Revenue Share (%), by Product 2025 & 2033
- Figure 46: Asia Pacific Cancer Biopsy Industry Volume Share (%), by Product 2025 & 2033
- Figure 47: Asia Pacific Cancer Biopsy Industry Revenue (Million), by Type 2025 & 2033
- Figure 48: Asia Pacific Cancer Biopsy Industry Volume (K Unit), by Type 2025 & 2033
- Figure 49: Asia Pacific Cancer Biopsy Industry Revenue Share (%), by Type 2025 & 2033
- Figure 50: Asia Pacific Cancer Biopsy Industry Volume Share (%), by Type 2025 & 2033
- Figure 51: Asia Pacific Cancer Biopsy Industry Revenue (Million), by Application 2025 & 2033
- Figure 52: Asia Pacific Cancer Biopsy Industry Volume (K Unit), by Application 2025 & 2033
- Figure 53: Asia Pacific Cancer Biopsy Industry Revenue Share (%), by Application 2025 & 2033
- Figure 54: Asia Pacific Cancer Biopsy Industry Volume Share (%), by Application 2025 & 2033
- Figure 55: Asia Pacific Cancer Biopsy Industry Revenue (Million), by End User 2025 & 2033
- Figure 56: Asia Pacific Cancer Biopsy Industry Volume (K Unit), by End User 2025 & 2033
- Figure 57: Asia Pacific Cancer Biopsy Industry Revenue Share (%), by End User 2025 & 2033
- Figure 58: Asia Pacific Cancer Biopsy Industry Volume Share (%), by End User 2025 & 2033
- Figure 59: Asia Pacific Cancer Biopsy Industry Revenue (Million), by Country 2025 & 2033
- Figure 60: Asia Pacific Cancer Biopsy Industry Volume (K Unit), by Country 2025 & 2033
- Figure 61: Asia Pacific Cancer Biopsy Industry Revenue Share (%), by Country 2025 & 2033
- Figure 62: Asia Pacific Cancer Biopsy Industry Volume Share (%), by Country 2025 & 2033
- Figure 63: Middle East and Africa Cancer Biopsy Industry Revenue (Million), by Product 2025 & 2033
- Figure 64: Middle East and Africa Cancer Biopsy Industry Volume (K Unit), by Product 2025 & 2033
- Figure 65: Middle East and Africa Cancer Biopsy Industry Revenue Share (%), by Product 2025 & 2033
- Figure 66: Middle East and Africa Cancer Biopsy Industry Volume Share (%), by Product 2025 & 2033
- Figure 67: Middle East and Africa Cancer Biopsy Industry Revenue (Million), by Type 2025 & 2033
- Figure 68: Middle East and Africa Cancer Biopsy Industry Volume (K Unit), by Type 2025 & 2033
- Figure 69: Middle East and Africa Cancer Biopsy Industry Revenue Share (%), by Type 2025 & 2033
- Figure 70: Middle East and Africa Cancer Biopsy Industry Volume Share (%), by Type 2025 & 2033
- Figure 71: Middle East and Africa Cancer Biopsy Industry Revenue (Million), by Application 2025 & 2033
- Figure 72: Middle East and Africa Cancer Biopsy Industry Volume (K Unit), by Application 2025 & 2033
- Figure 73: Middle East and Africa Cancer Biopsy Industry Revenue Share (%), by Application 2025 & 2033
- Figure 74: Middle East and Africa Cancer Biopsy Industry Volume Share (%), by Application 2025 & 2033
- Figure 75: Middle East and Africa Cancer Biopsy Industry Revenue (Million), by End User 2025 & 2033
- Figure 76: Middle East and Africa Cancer Biopsy Industry Volume (K Unit), by End User 2025 & 2033
- Figure 77: Middle East and Africa Cancer Biopsy Industry Revenue Share (%), by End User 2025 & 2033
- Figure 78: Middle East and Africa Cancer Biopsy Industry Volume Share (%), by End User 2025 & 2033
- Figure 79: Middle East and Africa Cancer Biopsy Industry Revenue (Million), by Country 2025 & 2033
- Figure 80: Middle East and Africa Cancer Biopsy Industry Volume (K Unit), by Country 2025 & 2033
- Figure 81: Middle East and Africa Cancer Biopsy Industry Revenue Share (%), by Country 2025 & 2033
- Figure 82: Middle East and Africa Cancer Biopsy Industry Volume Share (%), by Country 2025 & 2033
- Figure 83: South America Cancer Biopsy Industry Revenue (Million), by Product 2025 & 2033
- Figure 84: South America Cancer Biopsy Industry Volume (K Unit), by Product 2025 & 2033
- Figure 85: South America Cancer Biopsy Industry Revenue Share (%), by Product 2025 & 2033
- Figure 86: South America Cancer Biopsy Industry Volume Share (%), by Product 2025 & 2033
- Figure 87: South America Cancer Biopsy Industry Revenue (Million), by Type 2025 & 2033
- Figure 88: South America Cancer Biopsy Industry Volume (K Unit), by Type 2025 & 2033
- Figure 89: South America Cancer Biopsy Industry Revenue Share (%), by Type 2025 & 2033
- Figure 90: South America Cancer Biopsy Industry Volume Share (%), by Type 2025 & 2033
- Figure 91: South America Cancer Biopsy Industry Revenue (Million), by Application 2025 & 2033
- Figure 92: South America Cancer Biopsy Industry Volume (K Unit), by Application 2025 & 2033
- Figure 93: South America Cancer Biopsy Industry Revenue Share (%), by Application 2025 & 2033
- Figure 94: South America Cancer Biopsy Industry Volume Share (%), by Application 2025 & 2033
- Figure 95: South America Cancer Biopsy Industry Revenue (Million), by End User 2025 & 2033
- Figure 96: South America Cancer Biopsy Industry Volume (K Unit), by End User 2025 & 2033
- Figure 97: South America Cancer Biopsy Industry Revenue Share (%), by End User 2025 & 2033
- Figure 98: South America Cancer Biopsy Industry Volume Share (%), by End User 2025 & 2033
- Figure 99: South America Cancer Biopsy Industry Revenue (Million), by Country 2025 & 2033
- Figure 100: South America Cancer Biopsy Industry Volume (K Unit), by Country 2025 & 2033
- Figure 101: South America Cancer Biopsy Industry Revenue Share (%), by Country 2025 & 2033
- Figure 102: South America Cancer Biopsy Industry Volume Share (%), by Country 2025 & 2033
List of Tables
- Table 1: Global Cancer Biopsy Industry Revenue Million Forecast, by Product 2020 & 2033
- Table 2: Global Cancer Biopsy Industry Volume K Unit Forecast, by Product 2020 & 2033
- Table 3: Global Cancer Biopsy Industry Revenue Million Forecast, by Type 2020 & 2033
- Table 4: Global Cancer Biopsy Industry Volume K Unit Forecast, by Type 2020 & 2033
- Table 5: Global Cancer Biopsy Industry Revenue Million Forecast, by Application 2020 & 2033
- Table 6: Global Cancer Biopsy Industry Volume K Unit Forecast, by Application 2020 & 2033
- Table 7: Global Cancer Biopsy Industry Revenue Million Forecast, by End User 2020 & 2033
- Table 8: Global Cancer Biopsy Industry Volume K Unit Forecast, by End User 2020 & 2033
- Table 9: Global Cancer Biopsy Industry Revenue Million Forecast, by Region 2020 & 2033
- Table 10: Global Cancer Biopsy Industry Volume K Unit Forecast, by Region 2020 & 2033
- Table 11: Global Cancer Biopsy Industry Revenue Million Forecast, by Product 2020 & 2033
- Table 12: Global Cancer Biopsy Industry Volume K Unit Forecast, by Product 2020 & 2033
- Table 13: Global Cancer Biopsy Industry Revenue Million Forecast, by Type 2020 & 2033
- Table 14: Global Cancer Biopsy Industry Volume K Unit Forecast, by Type 2020 & 2033
- Table 15: Global Cancer Biopsy Industry Revenue Million Forecast, by Application 2020 & 2033
- Table 16: Global Cancer Biopsy Industry Volume K Unit Forecast, by Application 2020 & 2033
- Table 17: Global Cancer Biopsy Industry Revenue Million Forecast, by End User 2020 & 2033
- Table 18: Global Cancer Biopsy Industry Volume K Unit Forecast, by End User 2020 & 2033
- Table 19: Global Cancer Biopsy Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 20: Global Cancer Biopsy Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 21: United States Cancer Biopsy Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 22: United States Cancer Biopsy Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 23: Canada Cancer Biopsy Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 24: Canada Cancer Biopsy Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 25: Mexico Cancer Biopsy Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 26: Mexico Cancer Biopsy Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 27: Global Cancer Biopsy Industry Revenue Million Forecast, by Product 2020 & 2033
- Table 28: Global Cancer Biopsy Industry Volume K Unit Forecast, by Product 2020 & 2033
- Table 29: Global Cancer Biopsy Industry Revenue Million Forecast, by Type 2020 & 2033
- Table 30: Global Cancer Biopsy Industry Volume K Unit Forecast, by Type 2020 & 2033
- Table 31: Global Cancer Biopsy Industry Revenue Million Forecast, by Application 2020 & 2033
- Table 32: Global Cancer Biopsy Industry Volume K Unit Forecast, by Application 2020 & 2033
- Table 33: Global Cancer Biopsy Industry Revenue Million Forecast, by End User 2020 & 2033
- Table 34: Global Cancer Biopsy Industry Volume K Unit Forecast, by End User 2020 & 2033
- Table 35: Global Cancer Biopsy Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 36: Global Cancer Biopsy Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 37: Germany Cancer Biopsy Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 38: Germany Cancer Biopsy Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 39: United Kingdom Cancer Biopsy Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 40: United Kingdom Cancer Biopsy Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 41: France Cancer Biopsy Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 42: France Cancer Biopsy Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 43: Italy Cancer Biopsy Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 44: Italy Cancer Biopsy Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 45: Spain Cancer Biopsy Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 46: Spain Cancer Biopsy Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 47: Rest of Europe Cancer Biopsy Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 48: Rest of Europe Cancer Biopsy Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 49: Global Cancer Biopsy Industry Revenue Million Forecast, by Product 2020 & 2033
- Table 50: Global Cancer Biopsy Industry Volume K Unit Forecast, by Product 2020 & 2033
- Table 51: Global Cancer Biopsy Industry Revenue Million Forecast, by Type 2020 & 2033
- Table 52: Global Cancer Biopsy Industry Volume K Unit Forecast, by Type 2020 & 2033
- Table 53: Global Cancer Biopsy Industry Revenue Million Forecast, by Application 2020 & 2033
- Table 54: Global Cancer Biopsy Industry Volume K Unit Forecast, by Application 2020 & 2033
- Table 55: Global Cancer Biopsy Industry Revenue Million Forecast, by End User 2020 & 2033
- Table 56: Global Cancer Biopsy Industry Volume K Unit Forecast, by End User 2020 & 2033
- Table 57: Global Cancer Biopsy Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 58: Global Cancer Biopsy Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 59: China Cancer Biopsy Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 60: China Cancer Biopsy Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 61: Japan Cancer Biopsy Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 62: Japan Cancer Biopsy Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 63: India Cancer Biopsy Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 64: India Cancer Biopsy Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 65: Australia Cancer Biopsy Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 66: Australia Cancer Biopsy Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 67: South Korea Cancer Biopsy Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 68: South Korea Cancer Biopsy Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 69: Rest of Asia Pacific Cancer Biopsy Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 70: Rest of Asia Pacific Cancer Biopsy Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 71: Global Cancer Biopsy Industry Revenue Million Forecast, by Product 2020 & 2033
- Table 72: Global Cancer Biopsy Industry Volume K Unit Forecast, by Product 2020 & 2033
- Table 73: Global Cancer Biopsy Industry Revenue Million Forecast, by Type 2020 & 2033
- Table 74: Global Cancer Biopsy Industry Volume K Unit Forecast, by Type 2020 & 2033
- Table 75: Global Cancer Biopsy Industry Revenue Million Forecast, by Application 2020 & 2033
- Table 76: Global Cancer Biopsy Industry Volume K Unit Forecast, by Application 2020 & 2033
- Table 77: Global Cancer Biopsy Industry Revenue Million Forecast, by End User 2020 & 2033
- Table 78: Global Cancer Biopsy Industry Volume K Unit Forecast, by End User 2020 & 2033
- Table 79: Global Cancer Biopsy Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 80: Global Cancer Biopsy Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 81: GCC Cancer Biopsy Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 82: GCC Cancer Biopsy Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 83: South Africa Cancer Biopsy Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 84: South Africa Cancer Biopsy Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 85: Rest of Middle East and Africa Cancer Biopsy Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 86: Rest of Middle East and Africa Cancer Biopsy Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 87: Global Cancer Biopsy Industry Revenue Million Forecast, by Product 2020 & 2033
- Table 88: Global Cancer Biopsy Industry Volume K Unit Forecast, by Product 2020 & 2033
- Table 89: Global Cancer Biopsy Industry Revenue Million Forecast, by Type 2020 & 2033
- Table 90: Global Cancer Biopsy Industry Volume K Unit Forecast, by Type 2020 & 2033
- Table 91: Global Cancer Biopsy Industry Revenue Million Forecast, by Application 2020 & 2033
- Table 92: Global Cancer Biopsy Industry Volume K Unit Forecast, by Application 2020 & 2033
- Table 93: Global Cancer Biopsy Industry Revenue Million Forecast, by End User 2020 & 2033
- Table 94: Global Cancer Biopsy Industry Volume K Unit Forecast, by End User 2020 & 2033
- Table 95: Global Cancer Biopsy Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 96: Global Cancer Biopsy Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 97: Brazil Cancer Biopsy Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 98: Brazil Cancer Biopsy Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 99: Argentina Cancer Biopsy Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 100: Argentina Cancer Biopsy Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 101: Rest of South America Cancer Biopsy Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 102: Rest of South America Cancer Biopsy Industry Volume (K Unit) Forecast, by Application 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Cancer Biopsy Industry?
The projected CAGR is approximately 11.46%.
2. Which companies are prominent players in the Cancer Biopsy Industry?
Key companies in the market include Becton Dickinson and Company, Myriad Genetics Inc, BIOCEPT INC, Hologic Inc, ANGLE PLC, Danaher Corporation, Agilent Technologies Inc, Lucence Diagnostics Pte Ltd, Sysmex Corporation, MDx Health, Illumina Inc, Thermo Fisher Scientific, QIAGEN.
3. What are the main segments of the Cancer Biopsy Industry?
The market segments include Product, Type, Application, End User.
4. Can you provide details about the market size?
The market size is estimated to be USD 29.93 Million as of 2022.
5. What are some drivers contributing to market growth?
Rising Burden of Oncology Disorders and Increase in Adoption of Liquid Biopsies; Advancement in Technologies; Rising Awareness on Inherited Oncology Disorders and Genetic Testing.
6. What are the notable trends driving market growth?
Breast Cancer Segment is Expected to Grow During the Forecast Period.
7. Are there any restraints impacting market growth?
Associated Risks with Biopsy Procedures.
8. Can you provide examples of recent developments in the market?
In August 2022, Guardant Health gained US FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic (CDx) to choose patients with unresectable or metastatic HER2-mutant non-small cell lung cancer (NSCLC) with tumors that have activating HER2 (ERBB2) mutations for treatment with ENHERTU (fam-trastuzumab deruxtecan-nxki).
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million and volume, measured in K Unit.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Cancer Biopsy Industry," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Cancer Biopsy Industry report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Cancer Biopsy Industry?
To stay informed about further developments, trends, and reports in the Cancer Biopsy Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence